Aliases & Classifications for Proctitis

MalaCards integrated aliases for Proctitis:

Name: Proctitis 12 74 54 43 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3127
MeSH 43 D011349
NCIt 49 C38011
SNOMED-CT 67 3951002
ICD10 32 K62.89
UMLS 71 C0033246

Summaries for Proctitis

Disease Ontology : 12 A rectal disease that involves inflammation of the rectal mucosa, which results from infection, inflammatory bowel disease, or radiation. Sexually transmitted pathogens (Neisseria gonorrhoeae, Chlamydia trachomatis, herpes simplex virus 1 and 2, Treponema pallidum) and enteric pathogens (Campylobacter, Shigella, Salmonella) are involved in the disease. Symptoms are rectal discomfort and bleeding.

MalaCards based summary : Proctitis is related to radiation proctitis and ulcerative colitis, and has symptoms including rectal tenesmus An important gene associated with Proctitis is EPX (Eosinophil Peroxidase), and among its related pathways/superpathways are Innate Immune System and MAPK signaling pathway. The drugs Sucralfate and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include prostate, colon and cervix, and related phenotypes are cardiovascular system and hematopoietic system

Wikipedia : 74 Proctitis is an inflammation of the anus and the lining of the rectum, affecting only the last 6 inches... more...

Related Diseases for Proctitis

Diseases related to Proctitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 387)
# Related Disease Score Top Affiliating Genes
1 radiation proctitis 33.0 VEGFA TNF PECAM1 LTF KDR HEY2
2 ulcerative colitis 31.2 TNF MPO CRP CCR6
3 ischemic colitis 30.5 VEGFA CRP CCR6
4 collagenous colitis 30.5 RNASE3 MPO EPX
5 aseptic meningitis 30.4 TNF LTF CSF1
6 appendicitis 30.4 TNF MPO CRP
7 conjunctivitis 30.3 TNF RNASE3 MPO EPX
8 telangiectasis 30.3 VEGFA CCR6 ATM
9 gastroenteritis 30.3 TNF RNASE3 EPX CRP
10 proteasome-associated autoinflammatory syndrome 1 30.2 TNF RNASE3 MPO CRP
11 iron deficiency anemia 30.2 TNF LTF LCN2 CRP
12 chronic ulcer of skin 30.1 VEGFA TNF FGF2 CRP
13 toxic megacolon 30.1 TNF CRP CCR6
14 urethritis 30.1 TNF KLK3 CRP
15 ileitis 30.0 TNF MPO CCR6
16 acquired immunodeficiency syndrome 30.0 TNF PECAM1 CRP CCR6
17 hemorrhoid 30.0 KLK3 CRP APOLD1
18 lymphadenitis 29.9 TNF CRP CCR6
19 allergic hypersensitivity disease 29.8 TNF RNASE3 EPX CCR6
20 arthritis 29.8 VEGFA TNF CSF1 CRP CCR6
21 reactive arthritis 29.8 TNF MPO LTF CRP CCR6
22 vasculitis 29.8 TNF MPO LTF LCN2 CRP
23 neutropenia 29.8 MPO CYP3A5 CYP3A4 CSF1 CRP
24 peripheral nervous system disease 29.7 VEGFA TNF CRP CCR6
25 perinatal necrotizing enterocolitis 29.6 TNF LTF CRP CCR6
26 vascular disease 29.6 VEGFA TNF PECAM1 MPO FGF2 CRP
27 bacterial infectious disease 29.4 TNF LTF LCN2 CRP CCR6
28 exanthem 29.4 VEGFA TNF KDR CYP3A4 CRP CCR6
29 systemic lupus erythematosus 28.8 VEGFA TNF MPO LTF LCN2 CSF1
30 inflammatory bowel disease 28.7 VEGFA TNF PECAM1 MPO LTF LCN2
31 ovarian cancer 27.0 VEGFA TNF PECAM1 LCN2 KLK3 KDR
32 ulcerative proctitis 12.8
33 colitis 10.8
34 chlamydia 10.8
35 lymphogranuloma venereum 10.7
36 autoimmune inner ear disease 10.6 TNF MPO
37 diarrhea 10.6
38 drug reaction with eosinophilia and systemic symptoms 10.6 TNF CRP
39 microscopic polyangiitis 10.6 TNF MPO
40 prostate angiosarcoma 10.5 VEGFA PECAM1
41 inflammatory bowel disease 4 10.5 RNASE3 EPX
42 endomyocardial fibrosis 10.5 TNF RNASE3 EPX
43 chronic rhinitis 10.5 RNASE3 MPO EPX
44 eosinophil peroxidase deficiency 10.5 MPO EPX
45 herpes simplex 10.5
46 rheumatoid arthritis interstitial lung disease 10.5 TNF CRP
47 tacrolimus dose selection 10.5 CYP3A5 CYP3A4
48 pediatric angiosarcoma 10.5 VEGFA PECAM1
49 pollen allergy 10.5 RNASE3 MPO EPX
50 posterior scleritis 10.5 TNF CRP

Graphical network of the top 20 diseases related to Proctitis:



Diseases related to Proctitis

Symptoms & Phenotypes for Proctitis

UMLS symptoms related to Proctitis:


rectal tenesmus

MGI Mouse Phenotypes related to Proctitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 ATM CCR6 CRP CSF1 ENTPD1 FGF2
2 hematopoietic system MP:0005397 10.13 ATM CCR6 CSF1 ENTPD1 EPX FGF2
3 homeostasis/metabolism MP:0005376 10.13 ATM CCR6 CRP CSF1 ENTPD1 EPX
4 immune system MP:0005387 9.97 ATM CCR6 CRP CSF1 ENTPD1 EPX
5 liver/biliary system MP:0005370 9.61 CSF1 ENTPD1 HEY2 KDR LCN2 LTF
6 muscle MP:0005369 9.28 CSF1 ENTPD1 FGF2 HEY2 KDR MPO

Drugs & Therapeutics for Proctitis

Drugs for Proctitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sucralfate Approved Phase 4 54182-58-0
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3 Anti-Ulcer Agents Phase 4
4 Gastrointestinal Agents Phase 4
5 Antacids Phase 4
6 Calcineurin Inhibitors Phase 4
7
Budesonide Approved Phase 3 51333-22-3 63006 5281004
8
Inulin Approved, Investigational, Nutraceutical Phase 3 9005-80-5 24763
9 Anti-Asthmatic Agents Phase 3
10 Respiratory System Agents Phase 3
11 Hormone Antagonists Phase 3
12 Anti-Inflammatory Agents Phase 3
13 Autonomic Agents Phase 3
14 Bronchodilator Agents Phase 3
15 glucocorticoids Phase 3
16 Hormones Phase 3
17 Analgesics, Non-Narcotic Phase 3
18 Anti-Inflammatory Agents, Non-Steroidal Phase 3
19 Mesalamine Phase 3 89-57-6
20 Antirheumatic Agents Phase 3
21 Analgesics Phase 3
22 Cola Phase 3
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2 437-38-7 3345
24
Midazolam Approved, Illicit Phase 2 59467-70-8 4192
25
Propofol Approved, Investigational, Vet_approved Phase 2 2078-54-8 4943
26 Orange Approved Phase 2
27
Bisacodyl Approved Phase 2 603-50-9
28
Hyaluronic acid Approved, Vet_approved Phase 2 9004-61-9 53477741
29
Niclosamide Approved, Investigational, Vet_approved Phase 1, Phase 2 50-65-7 4477
30
Nitazoxanide Approved, Investigational, Vet_approved Phase 1, Phase 2 55981-09-4 41684
31 Anthelmintics Phase 1, Phase 2
32 Acidophilus Phase 2
33 Anti-Infective Agents Phase 1, Phase 2
34 Antiparasitic Agents Phase 1, Phase 2
35
Fluorouracil Approved Phase 1 51-21-8 3385
36 Tempol Investigational Phase 1 2226-96-2
37 Immunosuppressive Agents Phase 1
38 Immunologic Factors Phase 1
39 Anti-Bacterial Agents Phase 1
40 Antibiotics, Antitubercular Phase 1
41 Alkylating Agents Phase 1
42 Antioxidants Phase 1
43 Mitomycins Phase 1
44 Protective Agents Phase 1
45 Neuroprotective Agents Phase 1
46 Antimetabolites Phase 1
47 Radiation-Protective Agents Phase 1
48
Hydrocortisone acetate Approved, Vet_approved 50-03-3
49
Hydrocortisone Approved, Vet_approved 50-23-7 5754
50
Epinephrine Approved, Vet_approved 51-43-4 5816

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Argon Plasma Coagulation Plus Placebo or Oral Sucralfate for Chronic Radiation Proctopathy: a Randomized Placebo Controlled Trial Completed NCT01613534 Phase 4 Sucralfate;Placebo
2 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
3 A Single Center Pilot Study of CryoSpray Ablation(TM) to Determine Safety and Feasibility in Radiation Induced Proctitis (CSA LGI-2) Withdrawn NCT00756197 Phase 4
4 A Double-blind Placebo-controlled Trial of Dietary Supplementation With 15g/Day FOS for Five Weeks in Patients With Endometrial/Cervical Carcinoma or 7.5 Weeks in Patients With Prostate Carcinoma Undergoing Pelvic Radiotherapy. Unknown status NCT01414517 Phase 3
5 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Completed NCT01008423 Phase 3 Budesonide;Placebo
6 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Completed NCT01008410 Phase 3 Budesonide;Placebo
7 Efficacy of Symbiotic in the Reduction of Acute Radiation Proctitis Symptoms. A Randomized, Double-blind, Placebo-controlled Trial Completed NCT01901042 Phase 2, Phase 3
8 AN INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ESTABLISH THERAPEUTIC EQUIVALENCE OF 1000 mg MESALAMINE RECTAL SUPPOSITORIES AND CANASA® RECTAL SUPPOSITORIES (1000 mg MESALAMINE, USP) IN THE TREATMENT OF MILD TO MODERATE ULCERATIVE PROCTITIS Terminated NCT01172444 Phase 3 Mesalamine;Canasa;Placebo
9 A Phase 3, Open Label, Multicenter Study to Assess the Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis Terminated NCT01349673 Phase 3 Budesonide Foam
10 A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis Terminated NCT01016262 Phase 3 MAX-002;Placebo;Canasa®
11 Hyperbaric Oxygen Radiation Tissue Injury Study - Project HORTIS Terminated NCT00134628 Phase 3
12 Randomized, Double-blind, Multicentre Study to Compare the Efficacy and Safety of Budesonide Versus Mesalazine Suppository Versus a Combination Therapy of Budesonide/Mesalazine Suppositories in Patients With Acute Ulcerative Proctitis Completed NCT01966783 Phase 2 Budesonide 2 mg suppository;Budesonide 4 mg suppository;Mesalazine 1 g suppository;Budesonide 2 mg suppository/Mesalazine 1 g suppository
13 Assessment of the Photopill Capsule Treatment for Safety and Feasibility in Patients With Ulcerative Proctitis Completed NCT01837615 Phase 2
14 Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial. Completed NCT02104271 Phase 2
15 Recurrent Prostate Cancer After Irradiation Treated With Brachytherapy Remedial: Phase 2 Study Completed NCT01956058 Phase 2
16 A Phase I/IIA, Open-Label, Three-Stage Study to Investigate the Safety, the Efficacy and the Pharmacokinetics of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Procto-Sigmoiditis Recruiting NCT03521232 Phase 1, Phase 2 Niclosamide
17 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Recruiting NCT03302858 Phase 2
18 The Effect of Lactobacillus Reuteri ATCC PTA 4659 in Patients With Ulcerative Colitis Recruiting NCT03798210 Phase 2
19 Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis Active, not recruiting NCT03441893 Phase 1, Phase 2 Nitazoxanide 500Mg Oral Tablet;Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet;Mesalazine 250Mg
20 Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial Active, not recruiting NCT02895724 Phase 2 Medical Oxygen
21 Randomised, Double-blind, Placebo-controlled, Multicentre, Comparative Phase II Pilot Study on the Efficacy and Tolerability of an 8-week Rectal Treatment With 2 mg Budesonide or Placebo for the Prevention of Acute Radiation Proctitis Terminated NCT00828230 Phase 2 budesonide;Placebo foam
22 Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients Active, not recruiting NCT01655836 Phase 1
23 A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation With Concurrent 5-Fluorouracil and Mitomycin-C for Stage I-III Carcinoma of the Anal Canal Terminated NCT01324141 Phase 1 Tempol;5-Fluorouracil;Mitomycin-C
24 Randomized Trial of Argon Plasma Coagulation Versus Argon Plasma Coagulation and Hemospray in the Therapy of Radiation Proctitis Unknown status NCT02233933
25 QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®) Completed NCT02368743 mesalazine
26 Treatment of Hemorrhagic Radiation Proctitis Using the Halo System Completed NCT01103492
27 Retrospektive Analyse Der Radiotherapie Des Pelvinen Lymphabflusses Beim Lokalisierten Prostatakarzinom Vom Hochrisikotyp Anhand Der Klinikdatenbank 2010-2016 Completed NCT02998619
28 A Validation Study of the Gen-Probe APTIMA Combo2 (AC2) for Detecting Chlamydia Trachomatis and Neisseria Gonorrhoeae in Rectal Samples. Completed NCT00827697
29 Quality of Life Study in Patients With Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent Completed NCT02836379
30 The Safety of Proctofoam-HC in the Third Trimester of Pregnancy Completed NCT00405288 Proctofoam-HC®
31 Surveillance of the Cohort of Patients Overexposed in a Course of Conformational Radiotherapy for a Prostate Adenocarcinoma in Jean MONNET Hospital, Epinal, France. Epinal: Patients Overexposed for a Prostate Adenocarcinoma Completed NCT00773656
32 Prospective Pilot Study of Therapeutic Targets (TT) Tailored Chemotherapy (Ch) and Intensity Modulated Radiotherapy (IMRT) as Neoadjuvant Treatment in Patients With Rectal Carcinoma Completed NCT01366118 Therapeutic target tailored chemotherapy
33 A Phase II Randomized Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix Completed NCT00193804
34 Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease Completed NCT02025777
35 STI Screening as a Combined HIV Prevention Platform for MSM in Peru Completed NCT03010020
36 Expedited Partner Therapy as STI Control Among MSM in Peru Completed NCT01720654
37 Percutaneous Tibial Nerve Stimulation - PTNS: an Alternative Treatment Option for Chronic Therapy Resistant Anal Fissure Completed NCT03554421
38 Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treatment Completed NCT01684514
39 Autonomic and Cytokines Profiles of Patients With Ulcerative Proctitis Recruiting NCT03259659
40 Transverse Colostomy for Refractory Hemorrhagic Chronic Radiation Proctitis With Moderate to Severe Anemia: a Prospective Cohort Study Recruiting NCT03397901
41 China Medical University Hospital, Taichung, Taiwan Recruiting NCT03970863
42 Pelvic Radiation Injuries After Cancer Treatment: Symptoms, Quality of Life and Experiences Before, Along and After Hyperbaric Oxygenation Treatment Recruiting NCT03570229
43 A Randomized Open-label Trial Comparing Acute Toxicity in Patients With Gynecological Cancer Treated With Adjuvant Conventional Versus VMAT Radiotherapy. Recruiting NCT03899376
44 Effect of a Low Residue Diet in Comparison to the Dietary Recommendations From the INCan: A Randomized Clinical Trial to Assess Malnutrition, Gastrointestinal Toxicity and Quality of Life of Advanced Cervical Cancer Patients (IB2-IVA) Recruiting NCT03100409
45 Post Implantation Syndrome and Administration on NSAIDs in Patients Undergoing Endovascular Repair of an Abdominal Aortic Aneurysm Under General Anesthesia Recruiting NCT03727412 Drugs, Generic (Naprosyn);Placebo Oral Tablet
46 Initial Experience in Brazilian Single Center With High Intensity Focalized Ultrasound (HIFU) Prostate Cancer Therapy: Morbidity, Oncological and Functional Outcomes. Active, not recruiting NCT03255135
47 TOUR: Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study Enrolling by invitation NCT03772145
48 A Prospective Longitudinal Study on the Effect of Tight Control Management on Perianal Crohn's Disease Enrolling by invitation NCT03861689
49 Comiss Score Fore Detection of Cow's Milk Protein Allergy Not yet recruiting NCT03664076
50 Prospective Endoscopic Safety Evaluation of Late Rectal Mucosal Injury Following CyberKnife Radiosurgery for Clinically Localized Prostate Cancer Terminated NCT01618838

Search NIH Clinical Center for Proctitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


mesalamine

Cochrane evidence based reviews: proctitis

Genetic Tests for Proctitis

Anatomical Context for Proctitis

MalaCards organs/tissues related to Proctitis:

40
Prostate, Colon, Cervix, Bone, Breast, Lymph Node, Skin

Publications for Proctitis

Articles related to Proctitis:

(show top 50) (show all 2437)
# Title Authors PMID Year
1
Faecal calprotectin and lactoferrin values during irradiation of prostate cancer correlate with chronic radiation proctitis: results of a prospective study. 54 61
19504404 2009
2
A prospective study of faecal calprotectin and lactoferrin in the monitoring of acute radiation proctitis in prostate cancer treatment. 54 61
18938774 2008
3
A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. 54 61
17490827 2007
4
Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers. 54 61
15545170 2004
5
Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. 54 61
12377320 2002
6
Local release of human neutrophil lipocalin (HNL), IL-8, and TNF-alpha is decreased as response to topical prednisolone treatment in distal ulcerative colitis and proctitis. 54 61
12353856 2002
7
Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. 54 61
11889070 2002
8
Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. 54 61
10406252 1999
9
Inflammatory bowel disease versus Chlamydia trachomatis infection: a case report and revision of the literature. 61
31851086 2020
10
Expert Commentary on the Evaluation and Management of Radiation Proctitis. 61
32032143 2020
11
Evaluation and Management of Chronic Radiation Proctitis. 61
32032142 2020
12
MRI- and PET-Guided Interstitial Brachytherapy for Postsurgical Vaginal Recurrences of Cervical Cancer: Results of Phase II Study. 61
31682968 2020
13
Selection Criteria and Clinical Outcomes of Patients With Asymmetrical Cervical Cancer Treated With Various High-dose-rate Brachytherapy Techniques. 61
32014945 2020
14
Syphilitic proctitis imitating rectal malignancy. 61
31895208 2020
15
Effect of interval between preoperative radiotherapy and surgery on clinical outcome and radiation proctitis in rectal cancer from FOWARC trial. 61
31828956 2020
16
Granulomas, Proctitis, and HIV. Complex diagnosis with a simple treatment. 61
32017908 2020
17
Evaluating the predictive value of quantec rectum tolerance dose suggestions on acute rectal toxicity in prostate carcinoma patients treated with IMRT. 61
31889921 2020
18
Special Considerations in the GI Bleeding Patient. 61
31915424 2020
19
Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow-up in a Danish Population-based Inception Cohort. 61
31076743 2020
20
[Anal herpes simplex virus infections]. 61
31965208 2020
21
Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer. 61
31980834 2020
22
Linked color imaging improves visibility of ectatic vessels in radiation proctitis during argon plasma coagulation. 61
31917490 2020
23
Proctitis in gay and bisexual men. Are microscopy and proctoscopy worthwhile? 61
32001659 2020
24
Hydrogen Peroxide Enema-induced Proctitis in a Young Female: A Case Report. 61
32025395 2019
25
Clinical outcomes of external beam radiotherapy in patients with localized prostate cancer: Does dose escalation matter? 61
31332959 2019
26
Late toxicities of prostate cancer radiotherapy with and without hydrogel SpaceAOR insertion. 61
31520465 2019
27
A comprehensive review and update on ulcerative colitis. 61
30837080 2019
28
Post hemorrhoidectomy complications: CT imaging findings. 61
31927497 2019
29
Lymphogranuloma Venereum Proctitis. 61
31843597 2019
30
Time to include patients with ulcerative proctitis in clinical trials. 61
31696821 2019
31
Associations of clinical and dosimetric parameters with late rectal toxicities after radical intensity-modulated radiation therapy for prostate cancer: a single-centre retrospective study. 61
31796645 2019
32
Anorectal Crohn's Disease. 61
31676054 2019
33
Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. 61
31822581 2019
34
[HAL-RAR for the treatment of hemorrhoids - a new, non invasive method]. 61
31813242 2019
35
Chlamydia trachomatis: when the virulence-associated genome backbone imports a prevalence-associated major antigen signature. 61
31697227 2019
36
Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience. 61
31700629 2019
37
[Argon plasma coagulation effective treatment of solitary rectal ulcer syndrome]. 61
31769859 2019
38
Incidental finding of diffuse cavernous rectal haemangiomatosis during bowel cancer screening. 61
31775640 2019
39
IBD in India: Similar Phenotype but Different Demographics Than the West. 61
31770158 2019
40
A positive clinical experience of a long-term treatment pattern with leukocyte apheresis and Adacolumn in ulcerative proctitis. 61
31595764 2019
41
Short and long term response to argon plasma therapy for hemorrhagic radiation proctitis. 61
31595754 2019
42
Clinical Anastomotic Leakage After Rectal Cancer Resection Can Be Predicted by Pelvic Anatomic Features on Preoperative MRI Scans: A Secondary Analysis of a Randomized Controlled Trial. 61
31567929 2019
43
Preclinical Model of Perianal Fistulizing Crohn's Disease. 61
31774918 2019
44
Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma. 61
31397065 2019
45
A 30-year Trend Analysis in the Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015. 61
30989166 2019
46
A phase 2 randomized controlled trial of oral resistant starch supplements in the prevention of acute radiation proctitis in patients treated for cervical cancer. 61
31898677 2019
47
Inter-institutional comparison of treatment practice for cervical cancer with special emphasis on brachytherapy. 61
31749850 2019
48
Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities. 61
31131492 2019
49
Infectious proctitis due to syphilis and chlamydia: an exuberant presentation. 61
31545062 2019
50
Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. 61
31286233 2019

Variations for Proctitis

Expression for Proctitis

Search GEO for disease gene expression data for Proctitis.

Pathways for Proctitis

Pathways related to Proctitis according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 VEGFA TNF RNASE3 PECAM1 MPO LTF
2 12.65 VEGFA TNF KDR FGF2 CSF1
3
Show member pathways
12.64 VEGFA TNF KDR HEY2 FGF2 CSF1
4
Show member pathways
12.21 TNF MPO CSF1 CRP
5
Show member pathways
12.2 RNASE3 LTF LCN2 CCR6
6 12.17 VEGFA TNF KDR FGF2
7 11.88 VEGFA TNF PECAM1 KDR
8 11.73 VEGFA TNF LCN2 FGF2
9
Show member pathways
11.53 MPO CYP3A5 CYP3A4
10 11.4 VEGFA KDR FGF2
11 11.38 TNF KLK3 CSF1
12 11.37 VEGFA FGF2 CSF1
13 11.29 VEGFA KDR FGF2
14
Show member pathways
11.26 VEGFA KDR CSF1
15
Show member pathways
11.11 KDR CYP3A5 CYP3A4
16 10.88 VEGFA KDR FGF2
17 10.59 CYP3A5 CYP3A4
18 10.59 VEGFA KDR FGF2 CSF1
19 10.54 TNF MPO CSF1
20 10.31 MPO CYP3A5 CYP3A4

GO Terms for Proctitis

Cellular components related to Proctitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 VEGFA TNF RNASE3 MPO LTF LCN2
2 secretory granule GO:0030141 9.46 VEGFA MPO LTF KLK3
3 extracellular space GO:0005615 9.4 VEGFA TNF RNASE3 PECAM1 MPO LTF
4 phagocytic vesicle lumen GO:0097013 9.26 MPO LTF

Biological processes related to Proctitis according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.92 TNF PECAM1 KDR FGF2
2 positive regulation of protein phosphorylation GO:0001934 9.85 VEGFA TNF PECAM1 KDR
3 cytokine-mediated signaling pathway GO:0019221 9.85 VEGFA TNF LCN2 FGF2 CSF1
4 neutrophil degranulation GO:0043312 9.85 RNASE3 PECAM1 MPO LTF LCN2 EPX
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 VEGFA TNF PECAM1
6 positive regulation of endothelial cell proliferation GO:0001938 9.78 VEGFA KDR FGF2
7 positive regulation of MAP kinase activity GO:0043406 9.77 VEGFA TNF FGF2
8 vasculogenesis GO:0001570 9.76 VEGFA KDR HEY2
9 antimicrobial humoral response GO:0019730 9.74 RNASE3 LTF LCN2
10 humoral immune response GO:0006959 9.73 TNF LTF CCR6
11 positive regulation of cell migration GO:0030335 9.72 VEGFA PECAM1 KDR CSF1 ATM
12 positive regulation of cell adhesion GO:0045785 9.7 VEGFA TNF ATM
13 positive regulation of blood vessel endothelial cell migration GO:0043536 9.69 VEGFA KDR FGF2
14 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.65 VEGFA KDR FGF2
15 angiogenesis GO:0001525 9.65 VEGFA PECAM1 KDR FGF2 APOLD1
16 positive regulation of positive chemotaxis GO:0050927 9.62 VEGFA KDR
17 negative regulation of lipid storage GO:0010888 9.6 TNF CRP
18 lipid hydroxylation GO:0002933 9.58 CYP3A5 CYP3A4
19 drug catabolic process GO:0042737 9.54 CYP3A5 CYP3A4
20 positive regulation of gene expression GO:0010628 9.5 VEGFA TNF LCN2 HEY2 CSF1 CRP
21 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.49 VEGFA KDR
22 cardiac vascular smooth muscle cell development GO:0060948 9.43 VEGFA HEY2
23 alkaloid catabolic process GO:0009822 9.4 CYP3A5 CYP3A4
24 cell migration involved in sprouting angiogenesis GO:0002042 9.33 VEGFA KDR FGF2
25 defense response to bacterium GO:0042742 9.1 TNF RNASE3 MPO LTF LCN2 EPX

Molecular functions related to Proctitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.67 VEGFA TNF FGF2 CSF1
2 heparin binding GO:0008201 9.56 VEGFA MPO LTF FGF2
3 retinoic acid 4-hydroxylase activity GO:0008401 9.4 CYP3A5 CYP3A4
4 estrogen 16-alpha-hydroxylase activity GO:0101020 9.32 CYP3A5 CYP3A4
5 heme binding GO:0020037 9.26 MPO EPX CYP3A5 CYP3A4
6 testosterone 6-beta-hydroxylase activity GO:0050649 9.16 CYP3A5 CYP3A4
7 iron ion binding GO:0005506 8.92 LTF LCN2 CYP3A5 CYP3A4

Sources for Proctitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....